| Jul 8 |
IDEAYA Biosciences Soars on Cancer Drug Study Results
|
| Jul 8 |
Ideaya Biosciences: Poised For Success In Bladder And Lung Cancer?
|
| Jul 8 |
Ideaya stock jumps after positive study data from cancer study
|
| Jul 8 |
IDEAYA Announces Positive Interim Phase 2 Monotherapy Expansion Data for IDE397 a Potential First-in-Class MAT2A Inhibitor in MTAP-Deletion Urothelial and Lung Cancer
|
| Jul 5 |
IDEAYA Announces Investor Webcast to Report Clinical Data Update for IDE397 Phase 2 Monotherapy Expansion Dose in MTAP-Deletion Urothelial and Lung Cancer on Monday, July 8, 2024
|
| Jun 26 |
IDEAYA Biosciences initiates subject dosing in Phase I bladder cancer trial
|
| Jun 25 |
IDEAYA Biosciences Announces First-Patient-In for Phase 1 Clinical Trial Evaluating IDE397 and Trodelvy® Combination in MTAP-Deletion Bladder Cancer
|
| Jun 24 |
IDEAYA Biosciences Announces Clinical Program Updates for IDE397 a Potential First-in-Class Phase 2 MAT2A Inhibitor Targeting MTAP-Deletion Solid Tumors
|
| Jun 18 |
Ideaya Biosciences Continues Its Pursuit Of 'Synthetic Lethality'
|
| Jun 18 |
Investors in IDEAYA Biosciences (NASDAQ:IDYA) have seen impressive returns of 277% over the past five years
|
